DanDi Bioscience

Leaping Phase (2020~)

• 2025
  1. IND filing Phase II clinical study for Sepsis and super bacteria infection
  2. POC validation of an AD drug candidate : DD-A279 (peptide)
  3. Merged into HLB
• 2024
  1. Phase 1 Trial for Sepsis and Superbug Infection Treatment in USA
  2. Continue POC Validation of an Alzheimer's Therapeutic Candidate
• 2023
  1. Phase 1 clinical trial commenced for sepsis and superbacteria infection therapy
  2. Pre-clinical trials commenced for Alzheimer’s Disease therapy
• 2022
  1. Changed company name to HLB Science Inc.
  2. European phase 1 clinical trial approved for sepsis and superbacteria infection therapy
  3. Candidate discovery for Alzheimer’s Disease therapy
• 2021
  1. Pre-clinical trials in progress for sepsis and superbacteria infection therapy
• 2020
  1. Listed on KONEX Stock market
  2. Changed company address
  3. Selected for participation in ‘Infectious Diseases Prevention therapy program’ by the Korean Ministry of Health and Welfare

Growing Phase (2017~2019)

• 2019
  1. Selected for participation in an investment-linked project by the National Research Foundation of Korea
• 2018
  1. Changed largest shareholder (HLB Global)
• 2017
  1. Certification of Company’s R&D Department

Establishing Phase (2016)

• 2016
  1. Dandi BioSciences Inc. is founded